Lung cancer in never smokers: A review

Journal of Clinical Oncology

Volumn 25, Issue 5, 2007, Pages 561-570

  Subramanian, Janakiraman ^a   Govindan, Ramaswamy ^a  

^a USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASBESTOS; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HEAVY METAL; K RAS PROTEIN; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN P53; RADON; EPIDERMAL GROWTH FACTOR RECEPTOR; HORMONE;

ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CHROMOSOME ABERRATION; DISEASE ASSOCIATION; DNA METHYLATION; ENVIRONMENTAL EXPOSURE; ETHNIC DIFFERENCE; FUME; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HISTOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; OCCUPATIONAL EXPOSURE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RADIATION EXPOSURE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SMOKING; TREATMENT OUTCOME; UNITED STATES; VIRUS INFECTION; COOKING; FEMALE; GENETIC PREDISPOSITION; GENETICS; LUNG DISEASE; LUNG TUMOR; MALE; METABOLISM; MUTATION; ONCOGENE RAS; POLLUTANT; SEX RATIO;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOME ABERRATIONS; COOKERY; DNA METHYLATION; ENVIRONMENTAL POLLUTANTS; FEMALE; GENES, RAS; GENETIC PREDISPOSITION TO DISEASE; HORMONES; HUMANS; LUNG DISEASES; LUNG NEOPLASMS; MALE; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; SEX DISTRIBUTION; SEX FACTORS; SMOKING; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; TUMOR VIRUS INFECTIONS;

EID: 33947502512     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.8015     Document Type: Review

References (166)

1. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005
2. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54:594-606, 1993
3. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005
4. Gazdar AF: Lung cancer in never smokers: A different pathway. Am Soc Clin Oncol Educational Book, 2005, pp 619-621
5. Koo LC, Ho JH-C: Worldwide epidemiological patterns of lung cancer in non smokers. Int J Epidemiol 19:s14-s23, 1990 (suppl)
6. Tyczynski JE, Bray F, Parkin DM: Lung cancer in Europe in 2000: Epidemiology, prevention, and early detection. Lancet Oncol 4:45-55, 2003
7. Toh C-K, Wong E-H, Lim W-T, et al: The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: A retrospective analysis. Chest 126:1750-1756, 2004
8. Gürsel G, Levent E, Öztürk C, et al: Hospital based survey of lung cancer in Turkey, a developing country, where smoking is highly prevalent. Lung Cancer 21:127-132, 1998
9. Lee C, Kang KH, Koh Y, et al: Characteristics of lung cancer in Korea, 1997. Lung Cancer 30:15-22, 2000
10. Lam KY, Fu KH, Wong MP, et al: Significant changes in the distribution of histologic types of lung cancer in Hong Kong. Pathology 25:103-105, 1993
11. Kabat GC, Wynder EL: Lung cancer in nonsmokers. Cancer 53:1214-1221, 1984
12. el-Torky M, el-Zeky F, Hall JC: Significant changes in the distribution of histologic types of lung cancer: A review of 4928 cases. Cancer 65:2361-2367, 1990
13. Fontham ET, Correa P, Reynolds P, et al: Environmental tobacco smoke and lung cancer in nonsmoking women: A multicenter study. JAMA 271:1752-1759, 1994
14. Brownson RC, Alavanja MC, Caporaso N, et al: Epidemiology and prevention of lung cancer in nonsmokers. Epidemiol Rev 20:218-236, 1998
15. Dibble R, Langeburg W, Bair S, et al: Natural history of non-small cell lung cancer in non-smokers. J Clin Oncol 23:683s, 2005 (abstr 7252)
16. Toh CK, Gao F, Lim WT, et al: Neversmokers with lung cancer: Epidemiologic evidence of a distinct disease entity. J Clin Oncol 24:2245-2251, 2006
17. Yu IT, Chiu YL, Au JS, et al: Dose-response relationship between cooking fumes exposures and lung cancer among Chinese nonsmoking women. Cancer Res 66:4961-4967, 2006
18. Kreuzer M, Kreienbrock L, Müller KM, et al: Histologic types of lung carcinoma and age at onset. Cancer 85:1958-1965, 1999
19. Ko Y, Lee C, Chen M, et al: Risk factors for primary lung cancer among non-smoking women in Taiwan. Int J Epidemiol 26:24-31, 1997
20. Stockwell H, Goldman A, Lyman G, et al: Environmental tobacco smoke and lung cancer risk in nonsmoking women. J Natl Cancer Inst 84:1417-1422, 1992
21. Boffetta P, Agudo A, Ahrens W, et al: Multicenter case-control study of exposure to environmental tobacco smoke and lung cancer in Europe. J Natl Cancer Inst 90:1440-1450, 1998
22. Kubik AK, Zatloukal P, Tomasek L, et al: Lung cancer risk among Czech women: A case-control study. Prev Med 34:436-444, 2002
23. Vineis P, Alavanja M, Buffler P, et al: Tobacco and cancer: Recent epidemiological evidence. J Natl Cancer Inst 96:99-106, 2004
24. Hackshaw AK, Law MR, Wald NJ: The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ 315:980-988, 1997
25. Vineis P, Airoldi L, Veglia F, et al: Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. BMJ 330:277, 2005
26. Law MR, Hackshaw AK: Environmental tobacco smoke. Br Med Bull 52:22-34, 1996
27. Tredaniel J, Boffetta P, Saracci R, et al: Non-smoker lung cancer deaths attributable to exposure to spouse's environmental tobacco smoke. Int J Epidemiol 26:939-944, 1997
28. Wald NJ, Nanchahal K, Thompson SG, et al: Does breathing other people's tobacco smoke cause lung cancer? BMJ 293:1217-1222, 1986
29. Haustein KO: Health consequences of passive smoking. Wien Med Wochenschr 150:233-244, 2000
30. Hirayama T: Non-smoking wives of heavy smokers have a higher risk of lung cancer: A study from Japan. Br Med J (Clin Res Ed) 282:183-185, 1981
31. Brown K: Population risk of lung cancer from passive smoking, in Bayard S, Jinot J, Koppikar AM (eds): Respiratory Health Effects of Passive Smoking: Lung Cancer and Other Disorders. Washington, DC, Environmental Protection Agency, 1992
32. Wu A: Chapter 7: Carcinogenic effects, in Shopland DR, Zeise L, Dunn A (eds): Health Effects of Exposure to Environmental Tobacco Smoke. Bethesda, MD, National Cancer Institute, 1999
33. International Agency for Research on Cancer: Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 83:1-1438, 2004
34. Koo LC, Ho JH: Diet as a confounder of the association between air pollution and female lung cancer: Hong Kong studies on exposures to environmental tobacco smoke, incense, and cooking fumes as examples. Lung Cancer 14:S47-S61, 1996 (suppl 1)
35. Wu-Williams AH, Dai XD, Blot W, et al: Lung cancer among women in north-east China. Br J Cancer 62:982-987, 1990
36. Gao YT, Blot WJ, Zheng W, et al: Lung cancer among Chinese women. Int J Cancer 40:604-609, 1987
37. Qu YH, Xu GX, Zhou JZ, et al: Genotoxicity of heated cooking oil vapors. Mutat Res 298:105-111, 1992
38. Ko YC, Cheng LS, Lee CH, et al: Chinese food cooking and lung cancer in women nonsmokers. Am J Epidemiol 151:140-147, 2000
39. Wang TJ, Zhou BS, Shi JP: Lung cancer in nonsmoking Chinese women: A case-control study. Lung Cancer 14:S93-S98, 1996 (suppl 1)
40. Kleinerman R, Wang Z, Lubin J, et al: Lung cancer and indoor air pollution in rural china. Ann Epidemiol 10:469, 2000
41. Gao YT: Risk factors for lung cancer among nonsmokers with emphasis on lifestyle factors. Lung Cancer 14:S39-S45, 1996 (suppl 1)
42. Kleinerman RA, Wang Z, Wang L, et al: Lung cancer and indoor exposure to coal and biomass in rural China. J Occup Environ Med 44:338-344, 2002
43. Liu Q, Sasco AJ, Riboli E, et al: Indoor air pollution and lung cancer in Guangzhou, People's Republic of China. Am J Epidemiol 137:145-154, 1993
44. Shen XB, Wang GX, Huang YZ, et al: Analysis and estimates of attributable risk factors for lung cancer in Nanjing, China. Lung Cancer 14:S107-S112, 1996 (suppl 1)
45. Luo RX, Wu B, Yi YN, et al: Indoor burning coal air pollution and lung cancer: A case-control study in Fuzhou, China. Lung Cancer 14:S113-119, 1996 (suppl 1)
46. Zhou BS, Wang TJ, Guan P, et al: Indoor air pollution and pulmonary adenocarcinoma among females: A case-control study in Shenyang, China. Oncol Rep 7:1253-1259, 2000
47. Dai XD, Lin CY, Sun XW, et al: The etiology of lung cancer in nonsmoking females in Harbin, China. Lung Cancer 14:S85-S91, 1996 (suppl 1)
48. Wu A, Fontham E, Reynolds P, et al: Family history of cancer and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 143:535-542, 1996
49. Schwartz A, Yang P, Swanson G: Familial risk of lung cancer among nonsmokers and their relatives. Am J Epidemiol 144:554-562, 1996
50. Wu PF, Lee CH, Wang MJ, et al: Cancer aggregation and complex segregation analysis of families with female non-smoking lung cancer probands in Taiwan. Eur J Cancer 40:260-266, 2004
51. Sellers T, Bailey-Wilson J, Elston R, et al: Evidence for mendelian inheritance in the pathogenesis of lung cancer. J Natl Cancer Inst 82:1272-1279, 1990
52. Yang P, Schwartz AG, McAllister AE, et al: Lung cancer risk in families of nonsmoking probands: Heterogeneity by age at diagnosis. Genet Epidemiol 17:253-273, 1999
53. Bailey-Wilson JE, Amos CI, Pinney SM, et al: A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet 75:460-474, 2004
54. Keith RL, Miller YE: Lung cancer: Genetics of risk and advances in chemoprevention. Curr Opin Pulm Med 11:265-271, 2005
55. Bell DW, Gore I, Okimoto RA, et al: Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37:1315-1316, 2005
56. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792, 2005
57. Kwak EL, Sordella R, Bell DW, et al: Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 102:7665-7670, 2005
58. Kiyohara C, Ohno Y: Role of metabolic polymorphisms in lung carcinogenesis. Nippon Koshu Eisei Zasshi 46:241-249, 1999
59. Guengerich FP, Shimada T: Activation of procarcinogens by human cytochrome P450 enzymes. Mutat Res 400:201-213, 1998
60. Le Marchand LC, Guo C, Benhamou S, et al: Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). Cancer Causes Control 14:339-346, 2003
61. Kiyohara C, Wakai K, Mikami H, et al: Risk modification by CYP1A1 and GSTM1 polymorphisms in the association of environmental tobacco smoke and lung cancer: A case-control study in Japanese nonsmoking women. Int J Cancer 107:139-144, 2003
62. Bennett WP, Alavanja MCR, Blomeke B, et al: Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. J Natl Cancer Inst 91:2009-2014, 1999
63. Samet J: Radon and lung cancer. J Natl Cancer Inst 81:745-757, 1989
64. National Research Council, Board on Radiation Effects Research: Health Effects of Exposure to Radon, BEIR VI. Washington, DC, National Academy Press, 1998
65. Belinsky SA, Klinge DM, Liechty KC, et al: Plutonium targets the p16 gene for inactivation by promoter hypermethylation in human lung adenocarcinoma. Carcinogenesis 25:1063-1067, 2004
66. Samet JM, Eradze GR: Radon and lung cancer risk: Taking stock at the millennium. Environ Health Perspect 108:635-641, 2000 (suppl 4)
67. Field R, Steck D, Smith B, et al: Residential radon gas exposure and lung cancer: The Iowa Radon Lung Cancer Study. Am J Epidemiol 151:1091-1102, 2000
68. Alavanja M, Brownson R, Lubin J, et al: Residential radon exposure and lung cancer among nonsmoking women. J Natl Cancer Inst 86:1829-1837, 1994
69. Alavanja MC, Lubin JH, Mahaffey JA, et al: Residential radon exposure and risk of lung cancer in Missouri. Am J Public Health 89:1042-1048, 1999
70. Schoenberg JB, Klotz JB, Wilcox HB, et al: Case-control study of residential radon and lung cancer among New Jersey women. Cancer Res 50:6520-6524, 1990
71. Letourneau EG, Krewski D, Choi NW, et al: Case-control study of residential radon and lung cancer in Winnipeg, Manitoba, Canada. Am J Epidemiol 140:310-322, 1994
72. Krewski D, Lubin JH, Zielinski JM, et al: Residential radon and risk of lung cancer: A combined analysis of 7 North American case-control studies. Epidemiology 16:137-145, 2005
73. Selikoff IJ, Churg J, Hammond EC: Asbestos exposure and neoplasia. JAMA 188:22-26, 1964
74. Carbone M, Kratzke RA, Testa JR: The pathogenesis of mesothelioma. Semin Oncol 29:2-17, 2002
75. Mossman BT, Bignon J, Corn M, et al: Asbestos: Scientific developments and implications for public policy. Science 247:294-301, 1990
76. Hughes J, Weill H: Asbestos and Man-Made Fibers. New York, NY, Marcel Dekker, 1994
77. van Loon A, Kant I, Swaen G, et al: Occupational exposure to carcinogens and risk of lung cancer: Results from The Netherlands cohort study. Occup Environ Med 54:817-824, 1997
78. Camus M, Siemiatycki J, Meek B: Nonoccupational exposure to chrysotile asbestos and the risk of lung cancer. N Engl J Med 338:1565-1571, 1998
79. Magnani C, Leporati M: Mortality from lung cancer and population risk attributable to asbestos in an asbestos cement manufacturing town in Italy. Occup Environ Med 55:111-114, 1998
80. Landrigan PJ: Asbestos: Still a carcinogen. N Engl J Med 338:1618-1619, 1998
81. Public Health Service: 11th Report on Carcinogens. Washington, DC, National Toxicology Program, US Department of Health and Human Services, 2005
82. Waalkes MP: Cadmium carcinogenesis. Mutat Res 533:107-120, 2003
83. Nawrot T, Plusquin M, Hogervorst J, et al: Environmental exposure to cadmium and risk of cancer: A prospective population-based study. Lancet Oncol 7:119-126, 2006
84. Salnikow K, Su W, Blagosklonny MV, et al: Carcinogenic metals induce hypoxia-inducible factor-stimulated transcription by reactive oxygen speciesindependent mechanism. Cancer Res 60:3375-3378, 2000
85. Hecht SS: Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 91:1194-1210, 1999
86. Canver CC, Memoli VA, Vanderveer PL, et al: Sex hormone receptors in non-small-cell lung cancer in human beings. J Thorac Cardiovasc Surg 108:153-157, 1994
87. Beattie C, Hansen N, Thomas P: Steroid receptors in human lung cancer. Cancer Res 45:4206-4214, 1985
88. Stabile LP, Davis ALG, Gubish CT, et al: Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 62:2141-2150, 2002
89. Omoto Y, Kobayashi Y, Nishida K, et al: Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 285:340-347, 2001
90. Fasco MJ, Hurteau GJ, Spivack SD: Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol 188:125-140, 2002
91. Hershberger PA, Vasquez AC, Kanterewicz B, et al: Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res 65:1598-1605, 2005
92. Gasperino J, Rom WN: Gender and lung cancer. Clin Lung Cancer 5:353-359, 2004
93. Taioli E, Wynder EL: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 86:869-870, 1994
94. Blackman JA, Coogan PF, Rosenberg L, et al: Estrogen replacement therapy and risk of lung cancer. Pharmacoepidemiol Drug Saf 11:561-567, 2002
95. Schabath MB, Wu X, Vassilopoulou-Sellin R, et al: Hormone replacement therapy and lung cancer risk: A case-control analysis. Clin Cancer Res 10:113-123, 2004
96. Samet JM, Humble CG, Pathak DR: Personal and family history of respiratory disease and lung cancer risk. Am Rev Respir Dis 134:466-470, 1986
97. Osann K: Lung cancer in women: The importance of smoking, family history of cancer, and medical history of respiratory disease. Cancer Res 51:4893-4897, 1991
98. Brenner AV, Wang Z, Kleinerman RA, et al: Previous pulmonary diseases and risk of lung cancer in Gansu Province, China. Int J Epidemiol 30:118-124, 2001
99. Wu A, Fontham E, Reynolds P, et al: Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 141:1023-1032, 1995
100. Schabath MB, Delclos GL, Martynowicz MM, et al: Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk. Am J Epidemiol 161:412-422, 2005
101. Alavanja M, Brownson R, Boice J Jr, et al: Preexisting lung disease and lung cancer among nonsmoking women. Am J Epidemiol 136:623-632, 1992
102. Wang SY, Hu YL, Wu YL, et al: A comparative study of the risk factors for lung cancer in Guangdong, China. Lung Cancer:S99-S105, 1996 (suppl 1)
103. Mizushima Y, Kobayashi M: Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis: A review of Japanese cases. Chest 108:1272-1277, 1995
104. Turner-Warwick M, Lebowitz M, Burrows B, et al: Cryptogenic fibrosing alveolitis and lung cancer. Thorax 35:496-499, 1980
105. Kawai T, Yakumaru K, Suzuki M, et al: Diffuse interstitial pulmonary fibrosis and lung cancer. Acta Pathol Jpn 37:11-19, 1987
106. Hubbard R, Venn A, Lewis S, et al: Lung cancer and cryptogenic fibrosing alveolitis: A population-based cohort study. Am J Respir Crit Care Med 161:5-8, 2000
107. Wells C, Mannino DM: Pulmonary fibrosis and lung cancer in the United States: Analysis of the multiple cause of death mortality data, 1979 through 1991. South Med J 89:505-510, 1996
108. Beutner KR, Tyring SM: Human papillomavirus and human disease. Am J Med 102:9-15, 1997
109. Syrjanen K: Epithelial lesions suggestive of a condylomatous origin found closely associated with invasive bronchial squamous cell carcinomas. Respiration 40:150-160, 1980
110. Cheng Y-W, Chiou H-L, Sheu G-T, et al: The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res 61:2799-2803, 2001
111. Bohlmeyer T, Le TN, Shroyer AL, et al: Detection of human papillomavirus in squamous cell carcinomas of the lung by polymerase chain reaction. Am J Respir Cell Mol Biol 18:265-269, 1998
112. Syrjanen KJ: HPV infections and lung cancer. J Clin Pathol 55:885-891, 2002
113. Chen YC, Chen JH, Kradin R, et al: Lung adenocarcinoma and human papillomavirus infection. Cancer 101:1428-1436, 2004
114. Yankaskas JR, Haizlip JE, Conrad M, et al: Papilloma virus immortalized tracheal epithelial cells retain a well-differentiated phenotype. Am J Physiol 264:C1219-C1230, 1993
115. Zhao YL, Piao CQ, Hall EJ, et al: Mechanisms of radiation-induced neoplastic transformation of human bronchial epithelial cells. Radiat Res 155: 230-234, 2001
116. Willey JC, Broussoud A, Sleemi A, et al: Immortalization of normal human bronchial epithelial cells by human papillomaviruses 16 or 18. Cancer Res 51:5370-5377, 1991
117. Viallet J, Liu C, Emond J, et al: Characterization of human bronchial epithelial cells immortalized by the E6 and E7 genes of human papillomavirus type 16. Exp Cell Res 212:36-41, 1994
118. De Silva R, Whitaker NJ, Rogan EM, et al: HPV-16 E6 and E7 genes, like SV40 early region genes, are insufficient for immortalization of human mesothelial and bronchial epithelial cells. Exp Cell Res 213:418-427, 1994
119. Mornex JF, Thivolet F, De las Heras M, et al: Pathology of human brochioloalveolar carcinoma and its relationship to the ovine disease. Curr Top Microbiol Immunol 275:225-248, 2003
120. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990
121. Powell CA, Spira A, Derti A, et al: Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am J Respir Cell Mol Biol 29:157-162, 2003
122. Hibi K, Takahashi T, Yamakawa K, et al: Three distinct regions involved in 3p deletion in human lung cancer. Oncogene 7:445-449, 1992
123. Wong MP, Fung LF, Wang E, et al: Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers. Cancer Epidemiol Biomarkers Prev 97:1263-1270, 2003
124. Björkqvist AM, Husgafvel-Pursiainen K, Anttila S, et al: DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes Chromosomes Cancer 22:79-82, 1998
125. Pei JB, Balsara BR, Li W, et al: Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromosomes Cancer 31:282-287, 2001
126. Wong MP, Lam WK, Wang E, et al: Primary adenocarcinomas of the lung in nonsmokers show a distinct pattern of allelic imbalance. Cancer Res 62:4464-4468, 2002
127. Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, et al: Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res 61:1309-1313, 2001
128. Lane DP: Cancer: p53, guardian of the genome. Nature 358:15-16, 1992
129. Takahashi T, Nau MM, Chiba I, et al: p53: A frequent target for genetic abnormalities in lung cancer. Science 246:491-494, 1989
130. Hussain SP, Hofseth LJ, Harris CC: Tumor suppressor genes: At the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment. Lung Cancer 34:S7-S15, 2001 (suppl)
131. Hainaut P, Olivier M, Pfeifer GP: TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke: Lessons from the IARC TP53 mutation database. Mutagenesis 16:551-553, 2001
132. Vahakangas KH, Bennett WP, Castren K, et al: p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res 61:4350-4356, 2001
133. Toyooka S, Tsuda T, Gazdar AF: The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat 21:229-239, 2003
134. Gealy R, Zhang L, Siegfried JM, et al: Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. Cancer Epidemiol Biomarkers Prev 8:297-302, 1999
135. Pao W, Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions. J Clin Oncol 23:2556-2568, 2005
136. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
137. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
138. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346, 2005
139. Sonobe M, Manabe T, Wada H, et al: Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 93:355-363, 2005
140. Kosaka T, Yatabe Y, Endoh H, et al: Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 64:8919-8923, 2004
141. Huang S-F, Liu H-P, Li L-H, et al: High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10:8195-8203, 2004
142. Tomizawa Y, Iijima H, Sunaga N, et al: Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 11:6816-6822, 2005
143. Pan ZK, Zhang L, Zhang X, et al: Epidermal growth factor receptor mutation in Chinese patients with non-small cell lung cancer. Ai Zheng 24:919-923, 2005
144. Shih JY, Gow CH, Yu CJ, et al: Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 118:963-969, 2006
145. Hsieh RK, Lim KH, Kuo HT, et al: Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest 128:317-321, 2005
146. Tokumo M, Toyooka S, Kiura K, et al: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11:1167-1173, 2005
147. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004
148. Huncharek M, Muscat J, Geschwind J-F: K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: A combined analysis of 881 cases. Carcinogenesis 20:1507-1510, 1999
149. Rodenhuis S: Ras and human tumors. Semin Cancer Biol 3:241-247, 1992
150. Ahrendt SA, Decker PA, Alawi EA, et al: Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92:1525-1530, 2001
151. Siegfried JM, Gillespie AT, Mera R, et al: Prognostic value of specific KRAS mutations in lung adenocarcinomas. Cancer Epidemiol Biomarkers Prev 6:841-847, 1997
152. Slebos RJ, Hruban RH, Dalesio O, et al: Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst 83:1024-1027, 1991
153. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054, 2003
154. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428, 2002
155. Toyooka S, Maruyama R, Toyooka KO, et al: Smoke exposure, histologic type and geographyrelated differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 103:153-160, 2003
156. Toyooka S, Suzuki M, Tsuda T, et al: Dose effect of smoking on aberrant methylation in non-small cell lung cancers. Int J Cancer 110:462-464, 2004
157. Zochbauer-Muller S, Fong KM, Virmani AK, et al: Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61:249-255, 2001
158. Divine KK, Pulling LC, Marron-Terada PG, et al: Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers. Int J Cancer 114:400-405, 2005
159. Wang Y-C, Lu Y-P, Tseng R-C, et al: Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest 111:887-895, 2003
160. Gazdar AF, Shigematsu H, Herz J, et al: Mutations and addiction to EGFR: The Achilles 'heal' of lung cancers? Trends Mol Med 10:481-486, 2004
161. Nordquist LT, Simon GR, Cantor A, et al: Improved survival in never-smokers versus current smokers with primary adenocarcinoma of the lung. Chest 126:347-351, 2004
162. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899, 2005
163. Miller VA, Kris MG, Shah N, et al: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22:1103-1109, 2004
164. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
165. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005
166. Miller VA, Herbst R, Prager D, et al: Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE. J Clin Oncol 22:631s, 2004 (suppl; abstr 7061)